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Abstract
Objective—The aim of this study was to determine whether intravenous (IV) conjugated estrogens
(EST) acutely enhance the suppression of whole-body or regional subcutaneous adipose tissue (SAT)
lipolysis by insulin in postmenopausal women.
Research Methods and Procedures—We assessed whole-body lipolysis by [2H5]glycerol rate
of appearance (GlycRA) and abdominal and femoral SAT lipolysis (interstitial glycerol; GlycIS) by
subcutaneous microdialysis. Postmenopausal women (n = 12) were studied on two occasions, with
IV EST or saline control (CON), under basal conditions and during a 3-stage (4, 8, and 40 mU/m2/
min) hyperinsulinemic, euglycemic clamp. Ethanol outflow/inflow ratio and recovery of [13C]
glycerol during microdialysis were used to assess blood flow changes and interstitial glycerol
concentrations, respectively.
Results—Compared with CON, EST did not affect systemic basal or insulin-mediated suppression
of lipolysis (GlycRA) or SAT nutritive blood flow. Basal GlycIS in SAT was reduced on the EST
day. However, insulin-mediated suppression of lipolysis in SAT was not significantly influenced by
EST.
Discussion—These findings suggest that estrogens acutely reduce basal lipolysis in SAT through
an unknown mechanism but do not alter whole-body or SAT suppression of lipolysis by insulin.
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Introduction
Suppression of sex hormones in premenopausal women triggers an increase in adiposity with
a disproportionate increase in central fat mass (1,2). Similarly, postmenopausal women on
placebo treatment have an increased rate of fat accumulation, particularly in the abdominal
region, when compared with estrogen-treated women (3–6). These observations suggest that
fat accumulation occurs more readily in the estrogen-deficient state in a region-specific
manner. The mechanisms for these actions of estrogens remain unclear, but increased fat
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accumulation in the estrogen-deficient state could occur through enhanced triglyceride storage,
reduced fatty acid mobilization (i.e., lipolysis), and/or decreased fat oxidation. Further, it is
not known whether estrogens modulate fat accumulation by altering lipolysis during basal
conditions or in response to stimulation (e.g., β-adrenergic) or inhibition (e.g., insulin, α-
adrenergic). In vitro studies have demonstrated that femoral adipocytes are less lipolytic than
abdominal adipocytes as a result of increased sensitivity to insulin and α-adrenergic inhibition
(7–11). However, it is not known whether estrogens preferentially inhibit femoral lipolysis to
favor gluteal-femoral subcutaneous adipose tissue (SAT)1 accumulation, the predominant
region of fat storage in premenopausal women.
We and others have found that exogenous estrogens improve the glucoregulatory action of
insulin (12–14), even when administered acutely (14). However, there is a paucity of research
on the effect of estrogens on the anti-lipolytic action of insulin in humans. The importance of
determining whether estrogens improve the anti-lipolytic action of insulin is highlighted by
the contribution that adipocyte insulin resistance has on the pathogenesis of type 2 diabetes
(15). Moreover, the importance of conducting studies in humans is underscored by findings
that the regulation of adipose tissue metabolism by sex steroids is not uniform across species
(16). To our knowledge, the only study that has evaluated estrogen regulation of lipolysis in
postmenopausal women found that 2 months of transdermal estradiol treatment decreased basal
whole-body lipolysis but not adrenergic stimulation of lipolysis; suppression of lipolysis by
insulin was not measured (17). Although the measurement of whole-body glycerol appearance
is a good index of overall adipose tissue lipolysis, it cannot elucidate regional differences in
SAT lipolysis and includes glycerol derived from the hydrolysis of circulating triglycerides.
Thus, by directly measuring regional SAT lipolysis in vivo, we gain additional information
regarding the specific contribution of SAT lipolysis to net lipolytic activity. Further, by
administering estrogens intravenously, we were able to measure the acute effect on the anti-
lipolytic action of insulin in the absence of confounding factors that are introduced during
chronic administration of estrogens. We assessed the direct effect of estrogens on insulin action
independently of the first-pass hepatic effects of oral estrogens, opposition by progestins, and
estrogen-mediated changes over time in body composition.
The primary aim of the current study was to determine whether acute intravenous (IV)
administration of conjugated estrogens (EST) influences whole-body and regional SAT
lipolysis during basal conditions and during suppression by insulin. We hypothesized that IV
EST would enhance both whole-body and regional SAT suppression of lipolysis by insulin.
To test these hypotheses, we measured whole-body ([2H5]glycerol kinetics) and regional
(microdialysis of abdominal and femoral SAT) lipolysis under basal conditions and during a
3-stage hyperinsulinemic, euglycemic clamp procedure in postmenopausal women with and
without IV EST administration.
Research Methods and Procedures
Study Design
Whole-body lipolysis ([2H5]glycerol rate of appearance; GlycRA) and abdominal and femoral
SAT lipolysis (interstitial glycerol; GlycIS) were assessed in postmenopausal women on two
occasions, with (EST) and without [control (CON)] acute administration (IV bolus) of
conjugated estrogens (2.5 mg). Measurements were made under basal conditions and during a
3-stage hyperinsulinemic, euglycemic clamp (Figure 1). A qualitative index of SAT nutritive
blood flow (ethanol washout) was measured simultaneously with GlycIS.
1Nonstandard abbreviations: SAT, subcutaneous adipose tissue; IV, intravenous; EST, estrogen; GlycRA, glycerol rate of appearance;
GlycIS, interstitial glycerol concentration; CON, control; GCRC, General Clinical Research Center; FFA, free fatty acid; RR, relative
recovery; Epi, epinephrine; NEpi, norepinephrine; OVX, ovariectomized.
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Subjects
Twelve healthy, postmenopausal women not on hormone therapy were studied.
Postmenopausal status was defined as cessation of menses for at least one year, or hysterectomy
with a follicle stimulation hormone >30 IU/L. Women were excluded from the study if they
had: a history of hormone-sensitive cancer, fasting plasma glucose >7.0 mM, uncontrolled
hypertension (resting systolic blood pressure > 150 mm Hg or diastolic >90 mm Hg), thyroid
dysfunction (TSH <0.5 or >5.0 mU/L), hypertriglyceridemia (fasting triglycerides >4.5 mM),
or abnormal liver or renal function. The nature, purpose, and risks of the study were explained
verbally and in writing to each subject. All participants provided written informed consent to
participate in the study, which was approved by the Colorado Multiple Institutional Review
Board.
Body Composition
Total fat mass was determined by DXA using a Lunar DPX-IQ (Software v4.38, Lunar Co.,
Madison, WI). Waist circumferences were measured by the same technician at the narrowest
point between the lowest rib and the iliac crest.
Hyperinsulinemic, Euglycemic Clamp Procedure
Three-stage (4, 8, and 40 mU/m2/min) hyperinsulinemic, euglycemic clamps were
administered according to the methods of DeFronzo et al. (18) (Figure 1). Clamps were
performed at the General Clinical Research Center (GCRC) after a 12-hour fast. An IV catheter
was placed in an antecubital vein for the infusion of insulin and 20% dextrose. A second catheter
was placed retrograde to venous flow in the contralateral hand for blood sampling. The hand
was kept in a warming box maintained at 60 °C to produce arterialized blood samples (19).
After the 90-minute basal period, insulin was infused at a priming dose for 10 minutes (stepped
down each minute from 12 mU/m2/min) and then at a constant rate of 4 mU/m2/min for 80
minutes. For the second and third stages, the insulin infusion was increased to 8 and 40 mU/
m2/min, respectively, for 90 minutes. Additionally, a primed (1.5 µmol/kg), constant (~0.1
µmol/kg/min) infusion of [2H5]glycerol (Cambridge Isotope Laboratories, Inc., Andover, MA)
was delivered for 360 minutes (90-minute basal period and 90 minutes at each insulin stage)
to measure whole-body lipolysis. Plasma glucose concentration was measured every 5 minutes
during the insulin infusion by the glucose oxidase method on an automated glucose analyzer
(YSI Instruments, Yellow Springs, OH). The dextrose infusion was adjusted to maintain
plasma glucose at 5 mM. Blood samples were collected at time 0 (fasting) and at 60, 75, and
90 minutes of the basal period and each insulin stage for determination of insulin, estradiol,
estrone, catecholamines, free fatty acids (FFAs), and glycerol (concentration and isotope
enrichment). The clamp procedure was performed on two occasions (random order) in each
woman, with (EST) and without (CON) a 2.5 mg IV bolus of conjugated estrogens (Premarin,
Wyeth Pharmaceuticals Inc., Philadelphia, PA) administered at the beginning of the basal
period. The bolus was administered after the time 0 blood samples were collected and
immediately before the tracer infusion was initiated on the EST day. An average of 4 ± 2 weeks
separated the two testing days. The investigator and nursing staff conducting the clamps were
not blinded to the EST administration, but all blood and dialysate samples were analyzed in a
blinded fashion.
Whole-body Lipolysis
Plasma glycerol concentrations were measured by the GCRC Core Laboratory. The analysis
of [2H5]glycerol was done by the Colorado Clinical Nutrition Research Unit Mass
Spectrometry Core Laboratory using a modification of the negative ion chemical ionization
gas chromatography-mass spectrometry as previously described (20). The GlycRA over the last
30 minutes of each stage was calculated using the non-steady-state equation of Steele (21):
Van Pelt et al. Page 3
Obesity (Silver Spring). Author manuscript; available in PMC 2010 March 4.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
where F is the rate of infusion for [2H5]glycerol (0.10 µmol/kg/min), pV is the volume of
distribution (0.027 L/kg), C is the plasma glycerol concentration (µmol), E is the plasma isotope
enrichment, and t is time (min). Due to technical difficulty detecting [2H5]glycerol in samples
from 2 study participants (basal period samples for one woman and stage 2 samples for
another), complete GlycRA data were available for only 10 subjects. Thus, only these 10 paired
sets of GlycRA data are presented. Exclusion of these 2 women from the analysis of plasma
glycerol concentrations did not alter our results, therefore all 12 paired sets of plasma glycerol
are presented.
Regional SAT Lipolysis
Regional SAT lipolysis was evaluated by placing linear microdialysis probes (BAS custom
LM-3 probes, 3 cm membrane; BAS, Inc., West Lafayette, IN) in both abdominal and femoral
SAT. The microdialysis probes were soaked and perfused for a minimum of 14 hours overnight
in 5% ethanol and Ringer solution to remove the protective glycerol coating on the dialysis
membrane. On the morning of the clamp, microdialysis probes were perfused for an additional
30 minutes in Ringer solution to flush the ethanol solution. Probes were inserted under sterile
conditions into abdominal (2 probes lateral to the umbilicus; ~3 cm apart) and femoral (2 probes
mid-thigh; ~3 cm apart) SAT. Throughout the insulin clamp procedure, the probes were
perfused at 2.0 µL/min with Ringer solution containing 2.5 mM glucose, 200 µM [13C]glycerol,
and 5 mM ethanol. No samples were collected for at least 60 minutes after probe insertion to
allow for equilibration of the microdialysis system and to allow sufficient time for initial trauma
(i.e., local hyperemia) of probe insertion to subside (22). Glucose was included in the perfusate
to minimize the concentration gradient-mediated flow of glucose out of the interstitial fluid.
Ethanol was included in the perfusate to detect qualitative changes in nutritive blood flow in
the region surrounding the probe, as previously described (23). Ethanol concentrations in the
dialysates and perfusates were measured fluorometrically, and the data were expressed as the
outflow/inflow ratio ([ethanol]dialysate/[ethanol]perfusate), which is inversely related to nutritive
blood flow. The outgoing dialysate was collected in 15-min fractions (30 µL) throughout the
basal period and each insulin stage. Dialysate samples were initially stored at 4 °C and analyzed
within 24 hours for ethanol concentrations. Dialysate samples were then stored at −80 °C and
sent in batch to a commercial mass spectrometry laboratory (Metabolic Solutions, Inc., Nashua,
NH) for the analysis of [13C]glycerol enrichments and to East Carolina University (Greenville,
NC) for the spectophotometric measurement of glycerol concentrations using an automated
CMA600 Microdialysate Analyzer (CMA Microdialysis, Acton, MA). Because the
measurement of glycerol concentration by microdialysis is not a direct measure of interstitial
glycerol, [13C]glycerol isotopic tracer was included in the perfusate to calibrate dialysate
concentrations to the degree of equilibration of interstitial glycerol across the probe membrane,
as previously described (24). Thus, as an internal reference, relative recovery (RR) of glycerol
across the dialysis membrane was determined from the isotopic enrichment of [13C]glycerol
in the perfusate and the dialysate: RR = 1-([13C]glyceroldialysate/[ 13C]glycerolperfusate).
GlycIS was calculated from the measured dialysate glycerol concentrations corrected for the
RR of each probe at each individual time-point and then averaged over the final 30 min (2 15-
min collections) of each clamp stage and within each SAT region (across the two probes).
Blood Hormones and Metabolites
Blood samples were stored at −80 °C and analyzed in batch by the Core Laboratory of the
GCRC. Serum insulin concentrations were determined with a double-antibody
radioimmunoassay (Pharmacia Upjohn, Kalamazoo, MI). Plasma glycerol (R-Biopharm,
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Marshall, MI) and FFA (Wako Chemicals, Inc., Richmond, VA) were determined
enzymatically. Plasma estradiol and estrone were determined by double-antibody
radioimmunoassay (DPC, Los Angeles, CA, and DSL, Webster, TX; respectively). Plasma
epinephrine (Epi) and norepinephrine (NEpi) concentrations were determined by high-
performance liquid chromatography with electrochemical detection (Dionex DX-500; Dionex,
Sunnyvale, CA). Intra- and inter-assay coefficients of variation were as follows: insulin, 5.2%
and 9%; glycerol, 3.4% and 17.3%; FFA, 1.3% and 5.6%; estradiol, 6.0% and 11.2%; estrone,
8.7% and 8.6%; Epi, 5.7% and 8.5%; and NEpi, 4.1% and 7.7%. With the exception of insulin
and glucose data which were analyzed immediately, hormone and metabolite data for both
study days were batched for each subject and analyzed together.
Blood Lipids and Lipoproteins
Measurements of serum lipid and lipoprotein concentrations were done by the GCRC Core
Laboratory. Total cholesterol, high-density lipoprotein cholesterol, and triglycerides were
measured by automated enzymatic commercial kits on a Cobra Mira Plus instrument (Roche
Diagnostic Systems, Indianapolis, IN). Intra- and inter-assay coefficients of variation were as
follows: total cholesterol, 5.1% and 2.4%; high-density lipoprotein cholesterol, 4.5% and 2.9%;
triglycerides, 1.4% and 3.3%. Low-density lipoprotein cholesterol was calculated using the
Friedewald equation (25).
Statistics
Because this was the first study, to our knowledge, to evaluate the effect of estrogen on the
anti-lipolytic action of insulin, there were no data from which to estimate an effect size. Our
sample size of 12 was based on having power to detect an effect of estrogen on insulin-mediated
glucose disposal (14). Paired t tests were used to evaluate differences in serum hormone and
metabolite concentrations between EST and CON at time 0. A two-way (day × stage) repeated
measures ANOVA was used to evaluate changes in plasma glycerol concentrations, GlycRA,
FFA, Epi, NEpi, and insulin between days (EST vs. CON) and across insulin stages (basal
period and stages 1, 2, and 3). A three-way (SAT region × day × stage) repeated measures
ANOVA was used to evaluate changes in GlycIS and Ethanoloutflow/inflow. Based on study
results, the power to detect an interaction between estrogen and insulin on GlycRA was low
(8%). Main effects were considered when interactions were not significant. Statistical
significance was set at α = 0.05. Results are presented as mean ± standard deviation, unless
otherwise specified. All statistical analyses were conducted using SPSS for Windows software
(v12.0; SPSS, Inc., Chicago, IL).
Results
Subject characteristics are presented in Table 1. On average, women were moderately
overweight with abdominal obesity, as indicated by the large waist girth (>88 cm) but were
not hypertriglyceridemic (<1.7 mM). The IV bolus of EST successfully raised plasma estradiol
and estrone concentrations (Figure 2), such that mean estradiol concentrations throughout the
hyperinsulinemic, euglycemic clamp were comparable to premenopausal, mid-luteal phase
levels. At time 0, before EST infusion, there were no significant differences in serum hormone
and metabolite concentrations between the two test days, although plasma glycerol tended to
be lower on the EST day, compared with the CON day (74 ± 17 vs. 82 ± 25 µM, p = 0.10).
Mean time 0 and end-stage (average of 60, 75, and 90 min samples) serum hormone and
metabolite concentrations during the clamp are presented in Table 2. With the exception of
significantly lower plasma insulin during stage 3 on the EST day, there were no other EST-
related differences across the clamp stages in glucose, insulin, Epi, NEpi, or FFA. We
previously reported the effects of IV EST to reduce insulin concentrations without a decrease
in glucose disposal rates (14).
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Whole-body Lipolysis
There were no significant treatment day × insulin stage interactions for glycerol concentrations
or GlycRA. As expected, there was a dose-dependent main effect (p < 0.01) of insulin to
suppress serum glycerol concentrations and GlycRA with increasing levels of hyperinsulinemia
on both EST and CON days (Figure 3). There was a trend for a main effect (p = 0.09) of EST
to reduce plasma glycerol concentrations that reflected the trend for glycerol to be lower at
time 0 (i.e., before the administration of EST). There were no significant main effects of EST
on whole-body basal or insulin-mediated suppression of lipolysis (GlycRA). Insulin
concentrations were significantly reduced on the EST day compared with the CON day during
the third insulin stage, but GlycRA was not different, suggesting greater anti-lipolytic action of
insulin on the EST day. However, adjusting GlycRA for differences in insulin concentrations
did not significantly alter the results (data not shown).
Regional SAT Lipolysis
Changes in nutritive blood flow (Figure 4) over time did not significantly differ between sites
(femoral vs. abdominal), between conditions (EST vs. CON), or across insulin stages. There
were no significant interactions (SAT region × day × stage) for GlycIS. As expected, there was
a significant dose-dependent main effect (p < 0.001) of insulin to suppress GlycIS in both
abdominal and femoral SAT (Figure 5). There was a significant main effect (p = 0.001) of fat
region, such that GlycIS was higher in femoral than in abdominal SAT. There was also a
significant main effect of day (p < 0.05), such that GlycIS was lower on the EST day compared
with the CON day in femoral SAT (270 ± 34 vs. 331 ± 49 µM) and abdominal SAT (255 ± 40
vs. 286 ± 52 µM).
Discussion
The major findings of this study were that acute IV administration of EST reduced basal
GlycIS in both femoral and abdominal SAT, presumably reflecting a suppression of basal
lipolysis. However, whole-body basal lipolysis (GlycRA) was not significantly influenced by
EST. Contrary to our hypotheses, EST also did not alter whole-body or regional (abdominal
and femoral SAT) suppression of lipolysis by insulin. To our knowledge, the current study was
the first to evaluate whole-body and regional SAT lipolysis in response to acute EST
administration. Although we previously observed an acute effect of EST to improve the whole-
body glucoregulatory action of insulin (14), the present analysis found no significant effects
of EST on the whole-body or regional SAT anti-lipolytic action of insulin. Further, we
previously observed an acute effect of EST to reduce serum glycerol concentrations during
hyperinsulinemia (14), but the present analysis revealed no change in GlycRA. The lack of
change in GlycRA, despite reduced insulin concentrations during the third insulin stage,
suggested an increased sensitivity to the anti-lipolytic action of insulin. However, GlycRA
adjusted for insulin concentration was not different on the CON and EST days. Thus, the
reduced serum glycerol (adjusted for insulin concentrations) that we previously observed in
response to acute estrogen administration (14) may have reflected an increased clearance of
glycerol from the circulation.
Estrogens and Whole-body Lipolysis
Limited data are available regarding the in vivo effects of estrogens on lipolysis. A previous
study of postmenopausal women demonstrated that basal whole-body lipolysis was suppressed
in response to 2 months of transdermal estradiol treatment (13). In contrast, in our current
study, basal whole-body lipolysis was not altered in response to acute IV conjugated estrogen
administration, suggesting that duration of estrogen exposure or the route of administration
may be important. We are not aware of any published studies that have evaluated the effects
of estrogen therapy on insulin-mediated suppression of lipolysis.
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Estrogens and Regional Adipose Tissue Metabolism
Studies of sex hormone administration or suppression highlight the importance of estrogens
as a determinant of regional fat accumulation. Postmenopausal women treated with exogenous
estrogens have demonstrated an attenuated rate of fat accumulation compared with those on
placebo (6,26–28). The attenuation of fat accumulation by estrogens may be specific to the
abdominal region, since leg fat mass either did not change (28) or increased (26) in response
to hormone treatment. Additionally, in premenopausal women treated with a gonadotropin-
releasing hormone agonist for 4 months to suppress endogenous sex hormones, there were
significant increases in trunk (7.5% to 10%) but not leg (<2%) fat mass (2,29). Taken together,
these previous studies support a role for estrogens in the regulation of regional fat accumulation,
such that excess fat is stored in the gluteal-femoral, rather than the abdominal, region in the
estrogen-sufficient state. Consistent with these studies, the acute administration of estrogens
to postmenopausal women appeared to reduce basal lipolysis in SAT, particularly in the
femoral region, supporting a role for estrogens in regional fat deposition.
The mechanisms by which estrogens regulate regional fat metabolism remain uncertain.
Studies of changes in regional lipolysis in response to sex-hormone perturbations are lacking.
To our knowledge, the current study was the first to manipulate estrogens prospectively to
evaluate changes in abdominal and femoral SAT lipolysis (interstitial glycerol rate of
appearance) in humans. Previous cross-sectional studies of menopause-related differences in
regional adipocyte lipolysis in vitro have yielded conflicting results. One study observed higher
sensitivity to β-adrenergic stimulation of lipolysis in subcutaneous abdominal adipocytes than
in femoral adipocytes from premenopausal, but not postmenopausal, women (30). This might
suggest that the protection against abdominal fat accumulation in premenopausal women is
linked to the ability to mobilize fatty acids from that region. However, in a comparison of peri-
and postmenopausal women, there were no differences in β-adrenergic stimulation of lipolysis
in either subcutaneous abdominal or gluteal adipocytes (31). These cross-sectional
comparisons do not reveal definitive mechanisms for menopause-related differences in
regional adipocyte metabolism, and, to our knowledge, there have been no published studies
of the effects of sex hormone suppression or estrogen therapy comparing both abdominal and
femoral SAT lipolysis in humans. Thus, our prospective study provides novel preliminary data
for an effect of estrogens on regional SAT lipolysis in postmenopausal women.
To our knowledge, the only study that has evaluated the effect of estrogens on regional SAT
lipolysis in vivo used rodents and assessed only adrenergic-mediated lipolysis. Darimont et al.
(32) used microdialysis to assess β-adrenergic stimulation of lipolysis in vivo in parametrial
adipose tissue of ovariectomized (OVX) rats. They found that 7 days of estradiol treatment
increased isoproterenol-stimulated lipolysis in OVX rats back to pre-OVX diestrous levels,
suggesting an effect of estradiol on adipose tissue β-adrenergic stimulation. Because the
regulation of adipose tissue metabolism by sex steroids is not uniform across species (16), it
is not clear whether these results are relevant to humans. However, there is some evidence to
support a role of estrogens in adrenergic-mediated SAT lipolysis. Pederson et al. (33) evaluated
the effects of estradiol on abdominal α2-adrenergic receptor mRNA expression in
subcutaneous and visceral abdominal adipose tissue samples obtained from postmenopausal
women undergoing surgery for severe obesity (gastric banding). They found that estradiol
acutely (24-h in vitro incubation) up-regulated anti-lipolytic α2-adrenergic receptors in
subcutaneous, but not visceral, abdominal adipose tissue. This would suggest a greater anti-
lipolytic responsiveness in abdominal subcutaneous compared with visceral adipose tissue.
The effect of estradiol on femoral adipocyte α2-adrenergic receptors was not studied (33).
Thus, estradiol may affect SAT lipolysis through adrenergic-mediated mechanisms, but there
are not sufficient data to draw firm conclusions. Importantly, none of the aforementioned
studies (30–33) evaluated insulin-mediated suppression of lipolysis, a significant gap in the
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literature given the importance of adipocyte-mediated effects in the progression of insulin
resistance (15). The current study was the first to evaluate whether estrogens affect insulin-
mediated suppression of lipolysis in abdominal and femoral SAT in postmenopausal women.
Although our in vivo data do not support a role for IV estrogens to acutely alter insulin-mediated
suppression of lipolysis in femoral or abdominal SAT of postmenopausal women, estrogens
reduced basal lipolysis (as measured by GlycIS) ~16% in femoral SAT and ~8% in abdominal
SAT. If this reduction in SAT lipolysis persists with prolonged estrogen treatment, this would
suggest that estrogens suppress the mobilization of FFA from SAT during basal conditions,
which could be a contributing mechanism for the propensity of premenopausal women to
accumulate SAT, particularly in the femoral region. Additionally, basal lipolysis was lower in
abdominal than in femoral SAT in our estrogen-deficient postmenopausal women, possibly
contributing to the promotion of fat storage in the abdominal region after menopause.
Potential Mechanisms for Regulation of Lipolysis by Estrogens
The mechanisms by which estrogens regulate basal SAT lipolysis remain unclear. In vitro data
support both genomic and non-genomic actions of estrogen in adipose tissue (16). There is
increasing evidence that estrogens act through non-genomic mechanisms at the plasma
membrane level, including the cyclic adenosine monophosphate and phosphoinositide
cascades (16,34–37). Presumably, the effects of acute IV estrogen administration on basal
lipolysis in the current study were through such rapid non-genomic mechanisms. To our
knowledge, the only study that has investigated the effect of estrogen on a mediator of regional
SAT lipolysis (LPL activity) in humans administered estrogens for 3 weeks (i.e., long enough
for genomic mechanisms to occur) (38). In that study, treatment of postmenopausal women
with oral ethinyl estradiol (50 µg/d) for 3 weeks resulted in increased adipose tissue lipoprotein
lipase activity in femoral, but not abdominal, adipocytes (38). Thus, estrogens may influence
femoral SAT basal lipolysis through transcriptional effects on adipose tissue lipoprotein lipase,
possibly promoting the storage of triglyceride in femoral adipocytes. Rapid non-genomic
mechanisms have not been evaluated in human abdominal and femoral SAT, and the current
study was not designed to address such mechanisms. However, the findings that estrogens
suppressed basal, but not insulin-mediated, femoral, and abdominal SAT lipolysis, suggest
mechanisms that are not regulated by insulin.
Study Limitations
The current study had limitations that should be taken into account. First, use of the ethanol
technique to monitor adipose tissue nutritive blood flow provides a qualitative, rather than a
quantitative, evaluation of blood flow. Although regional differences in SAT blood flow have
been detected in response to exercise and angiotensin II (39,40), the ethanol technique may
not be sensitive enough to detect regional blood flow differences in response to estrogens or
insulin. Further, the possibility that there were quantitative day-to-day differences in nutritive
blood flow cannot be excluded. If nutritive blood flow was higher on the EST day compared
with the CON day, then the decreased GlycIS may have been the result of increased local
clearance of glycerol rather than reduced basal lipolysis. Nevertheless, the stability of
Ethanoloutflow/inflow throughout the experiments suggests that estrogens and insulin had little
effect on regional SAT nutritive blood flow.
Second, there is evidence that dose, route, and duration of estrogen administration are important
determinants of the effects on insulin action (12,41,42). Therefore, our findings may be specific
to the IV administration of a single 2.5 mg dose of conjugated estrogens that raised plasma
estradiol into the premenopausal, mid-luteal range.
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Third, it is not known why whole body lipolysis did not decrease despite the apparent reductions
in abdominal and femoral SAT lipolysis. It is possible that differences in abdominal and
femoral basal lipolysis on the EST and CON days reflected day-to-day variability, rather than
an effect of EST; GlycIS before EST infusion (time 0) were not measured. It is also possible
that estrogens were less effective in decreasing basal lipolysis in other tissues that were not
assessed (e.g., visceral adipose tissue, muscle), thereby contributing to the lack of a significant
decrease in net whole-body basal lipolysis.
In summary, acute IV administration of conjugated estrogens reduced basal lipolysis in SAT,
but basal whole-body lipolysis was not significantly altered. Estrogens did not alter insulin-
mediated suppression of either whole-body or SAT lipolysis. Suppression of basal lipolysis by
estrogens in subcutaneous femoral and abdominal adipose tissue could contribute to the
propensity of premenopausal women to accumulate fat in these regions. Additional studies will
be needed to confirm the effects of estrogens on adipose tissue basal lipolysis, particularly
during more prolonged estrogen therapy, and to elucidate the underlying mechanisms.
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Figure 1.
Illustration of the 3-stage hyperinsulinemic, euglycemic clamp protocol. IIR, insulin infusion
rate; GIR, glucose infusion rate. Blood samples were obtained at time 0 and at the 60, 75, and
90 min time-points during the basal period and stages 1 (4 mU/m2/min), 2 (8 mU/m2/min), and
3 (40 mU/m2/min). Conjugated estrogens (CE) were given as an IV bolus (2.5 mg) after the
fasting blood samples (time 0) on one of the two (randomly determined) testing days.
Van Pelt et al. Page 12
Obesity (Silver Spring). Author manuscript; available in PMC 2010 March 4.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2.
Mean (± standard error; n = 12) serum estradiol and estrone concentrations on the EST day at
time 0 (before IV conjugated estrogen bolus) and during the basal period and each stage of the
hyperinsulinemic, euglycemic clamp.
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Figure 3.
Mean (± standard error) serum glycerol concentrations (n = 12; top panel) and GlycRA (n =
10, bottom panel) during the basal period and each stage of the hyperinsulinemic, euglycemic
clamp on the estrogen day (EST) compared with the control day (CON). There was a significant
(p < 0.005) main effect of insulin stage, but not treatment day, on glycerol concentrations and
Ra.
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Figure 4.
Mean (± standard error; n = 12) femoral and abdominal subcutaneous adipose tissue nutritive
blood flow (ethanol outflow/inflow ratio) throughout the hyperinsulinemic, euglycemic clamp
on the estrogen day (EST) compared with the control day (CON).
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Figure 5.
Mean (± standard error; n = 12) femoral and abdominal subcutaneous adipose tissue interstitial
glycerol concentrations throughout the hyperinsulinemic, euglycemic clamp on the estrogen
day (EST) compared with the control day (CON). There were significant main effects of: 1)
insulin stage (p < 0.001); 2) treatment day (p < 0.05, EST<CON); and 3) fat region (p = 0.001,
abdominal<femoral) on interstitial glycerol concentrations.
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Table 1
Subject characteristics (n = 12)
Variable
Mean ±
standard deviation
Age (yr) 56 ± 4
Body mass (kg) 73.8 ± 15.2
BMI (kg/m2) 27.0 ± 5.0
Waist girth (cm) 94.9 ± 16.3
Fat mass (kg) 30.6 ± 11.2
Years menopausal 9 ± 5
Total cholesterol (mM) 5.17 ± 0.93
High-density lipoprotein
  cholesterol (mM) 1.47 ± 0.36
Low-density lipoprotein
  cholesterol (mM) 3.15 ± 0.85
Triglycerides (mM) 1.22 ± 0.56
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